Xcellerex has named Guy Broadbent as president and CEO. During his 25 year career Broadbent has gained substantial experience of the life sciences sector, most recently at Thermo Fisher Scientific.
Charles Bancroft has been elected chief financial officer (CFO) of Bristol-Myers Squibb (B-MS) by the company’s board of directors. Bancroft joined B-MS in 1984 and has since held positions of increasing responsibility in the company’s finance organisation.
MicroCHIPS has appointed Ajit Gill as president and CEO. Gill joins MicroCHIPS from Auspex Pharmaceuticals and also spent 14 years at Nektar Therapeutics, leading the company as it grew from a start-up to a public biopharmaceutical business.
Robert O’Holla has joined CeQur SA as executive vice president (EVP) for regulatory affairs. O’Holla worked at Johnson & Johnson for 33 years, including 18 years as worldwide VP for regulatory affairs.
KV Pharmaceutical has named Stephen Stamp as CFO and treasurer. Stamp has 27 years of finance experience at companies including Xanodyne Pharmaceuticals and Shire Pharmaceuticals.
Robert Forrester has been appointed chief operating officer at Forma Therapeutics. Forrester has previously worked at CombinatoRx and Coley Pharmaceutical.
Dendreon has named Varun Nanda as SVP of global operations. Nanda was previously SVP and global head of oncology operations at Roche/Genentech.
Dipak Panigrahi has joined QLT as SVP, research and development and chief medical officer. Panigrahi has previously worked at Alcon Laboratories and Merck & Co.
Inspire Pharmaceuticals has appointed Andrew Koven to the newly created position of EVP and chief administrative and legal officer. Koven has previously worked at Sepracor, Kos Pharmaceuticals and Lavipharm.